Valuation dashboard for NEXGEL, Inc. (NXGL) with P/E N/A, P/B 0.45, EV/EBITDA -4.57 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations.
Analysis Summary
NEXGEL, Inc. reported revenue of $11.4M in the most recent fiscal year, growing at a 5-year CAGR of 76.1%.
Trailing-twelve-month margins: gross margin 35.1%, operating margin -44.8%, net margin -51.3%.
At the current price of $0.25, NXGL has negative trailing earnings (P/E not meaningful) and an ROE of -133.10%. Market capitalisation stands at $2M.
Balance sheet quality for NXGL: current ratio of 1.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.45 |
| EV / EBITDA | -4.57 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-261.60 |
| vs Current Price | -105497.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NXGL | NEXGEL, Inc. | $2M | 0.45 | -133.1% | |
| 0R29.L | Intuitive Surgical, Inc. | $135.9B | 74.05 | 11.86 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.1B | 44.13 | 7.62 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.5B | 33.21 | 2.19 | 6.6% |
| BDX | Becton, Dickinson and Company | $49.0B | 54.89 | 2.05 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.81 | 5.23 | 23.9% |
| 0KW4.L | ResMed Inc. | $31.1B | |||
| MDLN | Medline Inc. | $27.6B | 38.36 | 2.44 | 10.8% |
Price
| Price | $0.25 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -133.10% |
| Return on Invested Capital | -41.80% |
| Return on Assets | -23.39% |
| Gross Margin | 35.07% |
| Operating Margin | -44.77% |
| Net Margin | -51.26% |
Related companies: ENLV · FEMY · GDTC · HBIO · IINN · MLSS · MTVA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NXGL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks